![\"\"](\"https:\/\/www.merckvaccines.com\/gardasil9\/wp-content\/uploads\/sites\/159\/2024\/04\/CAT_Doctor_Speaking_With_Family_144dpi_rgb.svg\")
H<\/b>elp protect<\/strong> against certain HPV-related<\/span> cancers<\/strong><\/h1><\/p>
\n\nBegin recommending GARDASIL 9 at age 9 for appropriate patients.<\/strong><\/p><\/div><\/div>\n\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n\n<\/div>\n\n\n\nYour recommendation matters\u2014<\/strong>A provider recommendation to patients 11 years and older was associated with increasing the odds of initiating HPV vaccination ~tenfold (pooled OR=10.1, 95% CI, 7.6, 13.4).1,a<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nOR, odds ratio; CI, confidence interval.<\/p>\n\n\n\n
<\/div>\n\n\n\na<\/sup>In a meta-analysis published in 2021, pooled analysis of 45 studies yielded 59 effect sizes (n=226,224) examining provider recommendation and HPV vaccine initiation among US adolescents aged 11-17 years and adults.<\/strong>1<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\n\nEmpower parents to initiate HPV vaccination for their child<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\nVaccinating may help prevent certain HPV-related cancers.2<\/sup><\/strong><\/p>\n\n\n\n<\/div>\n\n\n\nFor most people, HPV clears on its own.<\/strong> But for those who don\u2019t clear the virus, it could cause certain cancers and diseases later in life.2,3,4,5<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nEducate parents\u2014<\/strong>HPV vaccination is a type of cancer prevention for certain HPV-related cancers for both boys and girls.<\/p>\n\n\n\n<\/div>\n\n\n\nCertain HPV-related oropharyngeal cancers\u2014<\/strong>Certain oropharyngeal cancers were the most common HPV-related cancers in men and affect men more than women.b,6,7<\/sup> Not all oropharyngeal cancers are HPV-related.6<\/sup><\/p>\n\n\n\n<\/div>\n\n\n\nb<\/sup>Per 2012-2016 CDC data.<\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\nThe oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.<\/p>\n\n\n\n
<\/div>\n\n\n\n\n\n\nDosing schedule for GARDASIL 9<\/span><\/a><\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nReferences:<\/strong><\/h3><\/div>\n\n\n\n<\/div>\n\n\n\n\n- Oh NL, Biddell CB, Rhodes BE, Brewer NT. Provider communication and HPV vaccine uptake: a meta-analysis and systematic review. Prev Med<\/em>. 2021;148:106554. doi:10.1016\/j.ypmed.2021.106554<\/li>
- Meites E, Gee J, Unger E, Markowitz L. Epidemiology and Prevention of Vaccine-Preventable Diseases<\/em> (Pink Book). Chapter 11: Human Papillomavirus. Centers for Disease Control and Prevention. April 23, 2024. Accessed July 9, 2025. https:\/\/www.cdc.gov\/pinkbook\/hcp\/table-of-contents\/chapter-11-human-papillomavirus.html<\/li>
- HPV and oropharyngeal cancer. Centers for Disease Control and Prevention. September 17, 2024. Accessed September 25, 2024. https:\/\/www.cdc.gov\/cancer\/hpv\/oropharyngeal-cancer.html<\/span><\/li>
- Human papillomavirus (HPV) infection. Centers for Disease Control and Prevention. Last reviewed July 22, 2021. Accessed April 28, 2025. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/hpv.htm<\/li>
- Cancers caused by HPV. Centers for Disease Control and Prevention. March 3, 2025. Accessed March 5, 2025. https:\/\/www.cdc.gov\/hpv\/about\/cancers-caused-by-hpv.html<\/span><\/li>
- Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus\u2013attributable cancers \u2014 United States, 2012\u20132016. MMWR Morb Mortal Wkly Rep<\/em>. 2019;68:724-728. doi:http:\/\/dx.doi.org\/10.15585\/mmwr.mm6833a3<\/span><\/li>
- HPV and cancer. National Cancer Institute. Updated May 9, 2025. Accessed May 27, 2025. https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/risk\/infectious-agents\/hpv-and-cancer<\/li><\/ol><\/div>\n\n\n\n\n
Begin recommending GARDASIL 9 at age 9 for appropriate patients.<\/strong><\/p><\/div><\/div>\n\n<\/div> Your recommendation matters\u2014<\/strong>A provider recommendation to patients 11 years and older was associated with increasing the odds of initiating HPV vaccination ~tenfold (pooled OR=10.1, 95% CI, 7.6, 13.4).1,a<\/sup><\/p>\n\n\n\n OR, odds ratio; CI, confidence interval.<\/p>\n\n\n\n a<\/sup>In a meta-analysis published in 2021, pooled analysis of 45 studies yielded 59 effect sizes (n=226,224) examining provider recommendation and HPV vaccine initiation among US adolescents aged 11-17 years and adults.<\/strong>1<\/sup><\/p>\n\n\n\n Vaccinating may help prevent certain HPV-related cancers.2<\/sup><\/strong><\/p>\n\n\n\n For most people, HPV clears on its own.<\/strong> But for those who don\u2019t clear the virus, it could cause certain cancers and diseases later in life.2,3,4,5<\/sup><\/p>\n\n\n\n Educate parents\u2014<\/strong>HPV vaccination is a type of cancer prevention for certain HPV-related cancers for both boys and girls.<\/p>\n\n\n\n Certain HPV-related oropharyngeal cancers\u2014<\/strong>Certain oropharyngeal cancers were the most common HPV-related cancers in men and affect men more than women.b,6,7<\/sup> Not all oropharyngeal cancers are HPV-related.6<\/sup><\/p>\n\n\n\n b<\/sup>Per 2012-2016 CDC data.<\/p><\/div><\/div>\n\n\n\n The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.<\/p>\n\n\n\nEmpower parents to initiate HPV vaccination for their child<\/strong><\/h2><\/div>\n\n\n\n
References:<\/strong><\/h3><\/div>\n\n\n\n